Macrogol (polyethylene glycol) laxatives in children with functional constipation and faecal impaction: a systematic review by Candy, D & Belsey, J
Macrogol (polyethylene glycol) laxatives in children
with functional constipation and faecal impaction: a
systematic review
D Candy,
1 J Belsey
2
1Paediatric Gastroenterology
Service, Royal West Sussex
NHS Trust, Chichester, UK;
2JB
Medical Ltd, The Old Brickworks,
Chapel Lane, Little Cornard,
Sudbury, UK
Correspondence to:
Professor David C A Candy,
Royal West Sussex NHS Trust,
Chichester PO19 6SE, UK;
david.candy@rws-tr.nhs.uk
Accepted 9 September 2008
Published Online First
19 November 2008
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://
adc.bmj.com/info/unlocked.dtl
ABSTRACT
As the evidence base supporting the use of laxatives in
children is very limited, we undertook an updated
systematic review to clarify the issue. A comprehensive
literature search was carried out to identify randomised
controlled trials of polyethylene glycol (PEG) versus either
placebo or active comparator, in patients aged ,18 years
with primary chronic constipation. Outcomes were
assessed as either global assessments of effectiveness or
differences in defaecation rates. Seven qualifying studies
involving 594 children were identified. Five were
comparisons of PEG with lactulose, one with milk of
magnesia and one with placebo. Study duration ranged
from 2 weeks to 12 months. PEG was significantly more
effective than placebo and either equivalent to (two
studies) or superior to (four studies) active comparator.
Differences in study design precluded meaningful meta-
analysis. Lack of high quality studies has meant that the
management of childhood constipation has tended to rely
on anecdote and empirical treatment choice. Recent
publication of well designed randomised trials now
permits a more evidence-based approach, with PEG-
based treatments having been proven to be effective and
well-tolerated first-line treatment.
The last decade has seen a transformation in the
management of constipation in children. The
emphasis has changed from disimpacting the colon
with suppositories and enemas or manual removal
followed by polypharmacy with osmotic and
stimulant laxatives. Although individual practice
varies, nowadays there is widespread use of
macrogol (polyethylene glycol, PEG)-based laxa-
tives to empty the colon and keep it empty. It is
therefore timely to examine the evidence which
underpins this change in practice. At the same
time, efforts have been made to standardise the
nomenclature used to describe the clinical features
of constipation. This will avoid the use of
pejorative terms such ‘‘soiling’’ and facilitate
meta-analyses.
1–3
In many children, constipation is triggered by
experience of painful bowel movements, caused by
factors such as toilet training, changes in routine or
diet, stressful events, intercurrent illness or delay-
ing defaecation. The more time the faeces spend in
the colon, the more water is reabsorbed. The stools
then become harder and more difficult and painful
to pass. Faecal impaction occurs when there is an
accumulation of hard faeces in the rectum. Over
time, the rectum distends, the urge to defaecate
decreases, and there is a risk of faecal incontinence.
After several days without a bowel movement,
irritability, anorexia, abdominal distension and
cramps may occur.
4
Water makes up 75–80% of the weight of the
normal stool, but a difference of only 10% in
hydration will result in marked changes in stool
consistency.
5 PEG, a large molecular weight, water
soluble polymer has the capacity to form hydrogen
bonds with 100 molecules of water per molecule of
PEG (MW 3350).
6 When PEG is administered by
mouth, the resulting hydration of the colonic
content facilitates transit and painless defaecation
in a linear dose-dependent fashion.
7 Therefore PEG-
based laxatives when used in escalating doses can
also be used to completely remove faecal loading in
preference to rectally-administered treatments.
Standard management of chronic constipation
tends to begin with correction of dietary and
lifestyle factors which predispose to the condition,
in particular by increasing dietary fibre and fluid
intake.
8 However, dietary manipulation alone,
including the use of corn syrup, was successful in
resolving all symptoms of constipation in only 25%
of children aged up to 2 years in one US study.
9
Where simple measures fail, or where disimpac-
tion is required, the next step involves one or more
What is already known on this topic
c Current treatment of childhood constipation
tends to focus on oral rather than rectal
treatments.
c Agents such as lactulose and senna are still
widely used despite the lack of any meaningful
clinical trial evidence.
c Since the last systematic review was published,
several new randomised controlled trials have
suggested that polyethylene glycol-based
laxatives are effective in this patient group.
What this study adds
c Children with constipation treated with
polyethylene glycol (PEG)-based laxatives have
demonstrated consistently good outcomes.
c The efficacy of PEG is as good as or better than
lactulose or milk of magnesia over a wide range
of ages and treatment durations.
c PEG has the added advantage of being an
effective disimpacting agent.
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in England in 2005–6 shows that the most commonly chosen
agents are the osmotic laxatives, accounting for 47% of
prescriptions, stimulants (38%) and bulk-forming agents
(15%).
10
A comprehensive systematic review published in 2006
identified studies investigating treatments for childhood con-
stipation and faecal impaction.
11 Based on studies published up
to June 2005, the authors reported that, despite very limited
evidence, osmotic laxatives appeared to be the favoured option
in childhood constipation, although the relative benefits of the
various available treatments were unclear. They found no
evidence to support the use of stimulant laxatives or bulk-
forming agents in children.
Since 2005 several new randomised clinical trials investigating
the efficacy of PEG have been published. The intention of this
review, therefore, was to carry out a new literature search in
order to ascertain whether more precise guidance can now be
given with regard to osmotic laxatives and to further assess the
evidence for their use in the treatment of constipation in
children.
Literature search
A primary search for randomised controlled trials was carried
out in PubMed and EMBASE. The PubMed search used the
following MeSH terms, which were mapped to appropriate
EMTREE equivalents for the EMBASE search: Polyethylene
glycols OR Lactulose OR Senna-Extract OR Bisacodyl OR
{Picosulphate [Text word] OR Picosulfate [Text word]} AND
Constipation OR Defecation OR Cathartics AND Infant OR
Child, Preschool OR Child OR Adolescent AND Clinical Trial
[Publication type]. The same search was repeated using Review
[Publication type] in order to yield source material for a
secondary reference search.
Additional electronic searches using similar strategies were
carried out using the Cochrane Library and Google Scholar.
Reference lists of all identified clinical trials and reviews were
scrutinised to identify further potentially relevant studies.
Studies were examined to determine whether they complied
with the inclusion criteria listed in box 1.
RESULTS
Literature search
The initial PubMed search yielded 55 possibly relevant clinical
studies and 12 review articles. The EMBASE search yielded 45
possibly relevant clinical studies and 59 review articles. On
examination of full-text copies of the research papers, seven
were found to meet the inclusion criteria
12–18 while the rest were
rejected (fig 1).
The subsidiary search of other databases and the reference list
review yielded no additional qualifying studies.
The seven separate relevant studies that were identified for
consideration in the review included data on 594 children
treated for constipation (table 1). Study types were as follows:
c one randomised, controlled trial of PEG versus placebo
12
c five randomised, controlled trials of PEG versus lactulose
13–17
c one randomised, controlled trial of PEG versus milk of
magnesia.
18
Differences in study design, patient populations and treat-
ment protocols meant that meta-analysis could not be carried
out in a meaningful fashion. The results of the studies, together
with quality appraisals, are therefore detailed individually.
Treatment outcomes
PEG versus placebo
A total of 51 children were included in this randomised double-
blind crossover study that was carried out in six paediatric
outpatient centres.
12 All were aged between 2 and 11 years and
had at least a 3-month history of (2 complete defaecations per
week combined with one or more of the following: pain on
defaecation on >25% of days, >25% of bowel movements with
straining or >25% of movements with hard/lumpy stools.
Patients with current or previous faecal impaction were
excluded, as were those taking high doses of stimulant laxatives
with no effect.
Box 1 Inclusion and exclusion criteria for meta-analysis
Inclusion
c Randomised trial of osmotic laxative versus
– placebo
– active comparator
c Participants aged ,18 years
c Diagnosis of constipation of .3 months’ duration in the
absence of structural, endocrine or metabolic disease
c Quantitative effect on constipation recorded as outcome
Exclusion
c Retrospective analyses
c Non-comparative studies
c Constipation secondary to other diagnoses
c Not been published in a peer-reviewed journal
Qualitative appraisal for potential bias according to the following
aspects of design
c Inclusion criteria
c Quality of randomisation
c Presence and quality of blinding
c Washout in crossover studies
c Handling of withdrawals and dropouts
Data analysis
c Lack of consistency in outcomes
c Variation in design
c Recruitment strategy
c Diagnostic criteria
c Treatment protocols
NB. Studies precluded from inclusion by data analysis are
presented narratively. Figure 1 Literature search flow chart. PEG, polyethylene glycol; RCT,
randomised controlled trial.
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lytes (PEG+E) for 2 weeks, followed by placebo, after a 2-week
washout period, or the reverse. Dose was titrated according to
age and response and ranged from one to nine 6.9 g PEG+E
sachets daily. Randomisation was by computer allocation and
blinding was maintained using a double dummy approach. The
primary outcome measure was the number of complete
defaecations per week.
At the end of 6 weeks, four children failed to provide
sufficient bowel movement data for inclusion. Based on the
remaining 47 participants, mean PEG dosage used was 0.6 g/kg
in 2–6-year-old children and 0.7 g/kg in 7–11-year-old children.
There was a significant difference in the number of complete
defaecations: 3.12 vs 1.45, mean difference 1.64, p,0.001 and all
defaecations 5.68 vs 4.10, mean difference 1.58, p=0.003.
The authors also provided a per protocol analysis, which was
restricted to those with at least 7 days of data from each
treatment period and no concomitant laxative use. For this
subgroup of 36 patients, the benefit was somewhat enhanced:
mean defaecations 3.63 vs 1.63, mean difference 1.96, p,0.001.
PEG versus lactulose (five studies)
In the first study,
13 63 children with faecal impaction were
recruited for an open label evaluation of PEG+E for the
treatment of faecal impaction at a single paediatric centre. On
completion of this phase of the study, 58 progressed to
randomisation with lactulose or PEG+E as maintenance
therapy. Of the five who were not randomised, two withdrew
from the study and three failed to disimpact within 7 days. All
those entering the study were between 2 and 11 years of age
and had at least a 3-month history of constipation which had
failed to be controlled during normal outpatient management.
A randomisation list was supplied by a third party (the study
sponsor) in order to maintain concealment of allocation from
the investigator and both medications were supplied as dry
powders for the patient to reconstitute. Treatment was titrated
by response and was not dictated by protocol. If required,
patients were also allowed to use supplemental senna. The
primary outcome measure was the number of successful
defaecations per week on treatment, evaluated after 12 weeks.
The mean daily dose of PEG was 11.8 g and the mean dose of
lactulose was 24.1 g. Overall, 31% of lactulose patients required
senna, while no PEG+E patients needed senna. Of the 58
children who started, 10 failed to complete the study. Seven
patients taking lactulose reimpacted and were therefore with-
drawn, compared with none taking PEG+E. Two further
lactulose patients withdrew from the study, while one PEG
patient failed to complete a diary card. On-treatment efficacy
data were available for 53 patients, which provided the basis for
the primary intention to treat analysis: the mean number of
successful defaecations per week was significantly greater in
children given PEG+E than in those on lactulose: 9.4 vs 5.9,
mean difference 3.5, p=0.007.
The second study
14 investigated PEG 4000 versus lactulose.
Ninety six children were included in this randomised double-
blind parallel group study that was carried out in 30 paediatric
centres. Twenty two children were aged between 6 and
12 months and had at least a 1-month history of (1 stool per
day. The remaining 74 were aged 1–3 years and had at least a 3-
month history of (3 stools per week.
The randomisation strategy was not described. Medications
were supplied as dry powders for the patient to reconstitute and
a double-dummy approach employed in order to conceal
treatment allocation. In patients under 1 year of age, treatment
was limited to 4 g PEG or 3.33 g lactulose. In older children this
could be doubled, if required, with glycerol microenemas being
used if this still proved inadequate. No other laxatives were
permitted. The primary outcome of this study was a biochem-
ical assessment of safety after 6 and 12 weeks of treatment,
although stool frequency was also evaluated as a secondary
outcome.
Eight children failed to complete the study (four in each
group), although only one (in the lactulose group) dropped out
due to treatment failure. The median daily dose of PEG was 4 g
in both babies and older children. For lactulose, the dose was
3.33 g in babies and 3.66 g in older children. Thirty per cent of
children in the PEG group required enemas in the first half of
the study and 17% in the second half versus 43% and 41% in the
lactulose group (p=0.012). At 6 weeks, the median numbers of
stools per week in the PEG and lactulose groups, respectively,
were 8.5 vs 11, p=NS (babies) and 8 vs 6, p,0.013 (toddlers).
At 12 weeks, the equivalent results were 8.5 vs 11.5, p=NS
(babies) and 7 vs 6, p=NS (toddlers).
The third study
15 was a multicentre double-blind parallel
group study carried out in three hospitals, comparing PEG 3350
Table 1 Summary of included studies
Study Study duration Treatment Dosage Total n Success Defaecation rate
Thomson et al
12 2-Week
crossover
PEG 3350+E Mean 0.6–0.7 g/kg/day 51 83% 3.12 per week
Placebo N/A 51 21% 1.45 per week, p,0.001
Candy et al
13 12 Weeks PEG 3350+E Mean 11.8 g/day 28 – 9.4 per week
Lactulose Mean 24.1 g/day 30 – 7.9 per week, p=0.007
Dupont et al
14 12 Weeks PEG 4000 4–8 g/day¡enemas 51 – 8.5/7 per week
Lactulose 3.33–6.66 g/day¡enemas 45 – 11.5/6 per week, p=NS
(results: toddlers/babies)
Voskuijl et al
15 8 Weeks PEG 3350 Mean dose 5.4 g/day 50 56% 7.1 per week
Lactulose Mean dose 6.7 g/day 50 26%, p=0.02 6.4 per week, p,0.01
Gremse et al
16 2-Week
crossover
PEG 3350 0.3 g/kg/day 44 84% 14.8 per 2 weeks
Lactulose 1.3 g/kg/day 44 46%, p=0.002 13.5 per 2 weeks
Wang et al
17 2 Weeks PEG 4000 20 g/day 105 70% 7 per week (median)
Lactulose 10 g/day 111 40%, p,0.05 6 per week, p,0.05
Loening-Baucke et al
18 12 Months PEG 3350 Mean 0.6 g/kg/day 39 62% 6.8 per week
Milk of magnesia Mean 1.2 ml/kg/day 40 43%, p=NS 8.2 per week, p=NS
E, electrolytes; NS, not significant; PEG, polyethylene glycol.
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Participants were aged 6 months to 15 years and had to have
experienced two or more of the following for the preceding
3 months: ,3 bowel movements/week, .1 faecal incontinence/
week, large amount of stool every 7–30 days, palpable
abdominal/rectal mass.
Patients were randomised to receive PEG or lactulose at a
starting dose of 2.95 g or 6 g, respectively, for those aged under
6 years of age and 5.9 g or 12 g for those aged over 6 years of
age. The randomisation method was not described. Medications
were dispensed as dry powder in identical unlabelled sachets
with investigators and patients blinded to assignation. Doses
were titrated according to response, with the option to add in
bisacodyl if required. The primary outcomes were stool
frequency, faecal incontinence and overall treatment success
at 8 weeks.
Ninety one of the original 100 participants completed the
trial. Two patients in each group were lost to follow-up. One
patient withdrew from the PEG group due to dislike of the taste.
Two patients were withdrawn from the lactulose group as they
were found to be Helicobacter positive. The reason for with-
drawal for one patient in each group was not stated. At 8 weeks
the mean dose of PEG was 5.4 g/day and lactulose 13.9 g/day.
Bisacodyl was used by nine patients in the PEG group and 10 in
the lactulose group. Per protocol analysis showed a mean
weekly stool frequency at 8 weeks in the PEG and lactulose
groups, respectively, of 7.12 and 6.43 (p=NS). In both groups
there was significant improvement versus baseline. There was
also no significant difference in the frequency of faecal
incontinence. However, the rate of overall treatment success
(stool >3/week+incontinence ,1/fortnight) was significantly
better in PEG treated patients than in those on lactulose (56% vs
29%, p=0.02).
The fourth PEG-lactulose study
16 compared the use of PEG
3350 (without electrolytes) with lactulose in a randomised
crossover single centre design. Forty four children aged 2–
16 years were recruited. All had been referred to a specialist unit
for treatment of their constipation, but no explicit diagnostic
criteria are listed. Mean baseline stool frequency was 1.7 per
week. Patients were randomised to receive 10 g/m
2/day PEG or
1.3 g/kg/day lactulose at a fixed dose for 2 weeks. The
randomisation strategy is not detailed and treatment was not
blinded. Various outcomes were recorded, including stool
frequency, but it is unclear whether this was the primary
outcome.
Of the 44 patients who started the study, seven withdrew
due to lack of efficacy (six in the lactulose group and one in the
PEG group). No intention to treat analysis is given. A per-
protocol analysis, comparing the mean number of bowel
movements over 14 days, is presented for the remaining 37
patients: 14.8 vs 13.5 for PEG and lactulose, respectively. Based
on global assessment by the parent or guardian, 84% of the PEG-
treated patients achieved a satisfactory outcome compared with
46% of the lactulose-treated patients (p,0.002).
The final study
17 was a multicentre open label parallel group
study carried out in seven hospitals in China, comparing PEG
4000 with lactulose in 216 children. Participants were aged 8–
18 years (mean 11.2 years) and had a minimum 3-month
history of constipation, with a baseline Bristol Stool Form
Scale of less than 3.
Patients were randomised to receive PEG or lactulose at a
fixed dose of 20 g (PEG) or 10 g (lactulose) daily for 2 weeks.
Doses could be reduced according to clinical response, if
required. The randomisation method is not known and
treatment was not blinded. Outcomes assessed included stool
frequency, stool consistency and complete constipation remis-
sion rate.
All the participants completed the 14-day trial. Intention to
treat analysis showed an increase in median weekly stool
frequency in both groups. In PEG-treated patients the median
increased from 2/week at baseline to 7/week; in lactulose-
treated patients the median increased from 2/week at baseline
to 6/week. The between-treatments difference was statistically
significant. PEG was also significantly better in terms of the
proportions with complete resolution of constipation (72% vs
41%, p,0.05), mean Bristol Stool Form Scale (4.26 vs 3.63,
p,0.05) and resolution of abdominal pain (75% vs 57%,
p,0.05).
Brief summary of comparisons versus other laxatives (one study)
One study
18 has compared PEG 3550 with milk of magnesia in
a randomised open label parallel group study of 79 children
aged 4–16 years that lasted 12 months. There was no
significant difference between groups in either mean number
of bowel movements or episodes of faecal incontinence over
the course of the study. However, more children refused
treatment with milk of magnesia than with PEG (35% vs 5%,
p,0.001).
DISCUSSION
Previously published reviews on the management of childhood
constipation have commented on the lack of high quality
clinical trials in the field,
11 19–21 despite the widespread use of
laxatives. Although there remain significant gaps in the evidence
base, this literature review has demonstrated that the evidence
base of current clinical practice is now improving.
The placebo-controlled study of PEG+E by Thomson et al
12
defines a baseline proof of principle in a relatively mildly
affected population, while the two phase study by Candy et al
13
confirms that, once disimpacted, even severely affected children
can be maintained satisfactorily on low doses of PEG+E (the
mean daily dose was just under two paediatric dose sachets).
PEG+E could also be used as monotherapy whereas almost one
third of patients on lactulose required senna. No patient on
PEG+E reimpacted compared with almost one in four on
lactulose.
The five studies comparing PEG with lactulose
13–16 exhibit
some potentially important differences that prevent the results
being pooled in meta-analysis. Firstly, they involve three
different agents: PEG 3350, PEG 3350+E and PEG 4000. While
there is no a priori reason for supposing that these will behave
functionally differently as laxatives, one cannot necessarily
assume equivalence. Secondly, there are dose differences: in two
cases
13 15 the dose was titrated according to clinical response,
subject to an upper limit; in one case
14 a single titration was
permitted, with add-in therapy being required beyond that; and
in the other two studies
16 17 there was a fixed dose regime.
Finally, there are methodological concerns regarding the analysis
of the Gremse et al study
16 in that the presented results exclude
the patients who had withdrawn due to lack of efficacy, biasing
the results in favour of lactulose.
There have been no clinical studies which have compared PEG
with PEG+E. Of the seven studies reviewed, five compared PEG
and two compared PEG+E with either placebo or another
laxative.
Despite these issues, there appears to be a consensus amongst
the studies that treatment with PEG is more effective than with
Review
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advantage in terms of tolerability. PEG-based laxatives confer
the advantage that in high doses they can be used for
disimpaction, and, as they are not fermented by colonic
bacteria, do not result in increased gas production.
The comparison of PEG versus milk of magnesia was a well
designed and executed study relating to an agent that would
not be widely regarded as a first line agent in Europe.
Nonetheless, it adds to our understanding of these agents both
in terms of efficacy and tolerability.
CONCLUSIONS
Chronic constipation is associated with long term problems
including megarectum, reduced sensitivity of the rectum to the
presence of faeces, and abnormal gut motility. Effective
treatment of constipation has been shown to encourage the
rectum to revert to normal size.
22 Treatment has also been
shown to improve rectal sensitivity in patients who responded
to treatment, if not in those who were non-responders,
23 and
can improve gut motility in children for up to 3 years.
24
Nevertheless, even after treatment, chronic constipation may
have long term sequelae. Abnormal ano-rectal functions may
persist for years after cessation of treatment and recovery,
25
while constipation may continue to be an intermittent problem
in children with faecal impaction in whom gut motility has
returned to normal after treatment.
24 Managing chronic
constipation in children effectively and early in its course may
therefore be important in preventing long term defaecation
disorders. In order to achieve this it is essential that treatment
regimes are critically reviewed in the light of emerging evidence.
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